Allspring Global Investments Holdings LLC Reduces Holdings in Atrion Co. (NASDAQ:ATRI)

Allspring Global Investments Holdings LLC cut its holdings in Atrion Co. (NASDAQ:ATRI) by 23.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 239 shares of the medical instruments supplier’s stock after selling 73 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Atrion were worth $91,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Boston Trust Walden Corp lifted its stake in shares of Atrion by 4.8% in the 4th quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock valued at $13,292,000 after purchasing an additional 1,609 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Atrion by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock valued at $4,291,000 after buying an additional 243 shares during the period. Bank of New York Mellon Corp lifted its stake in Atrion by 2.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock worth $4,134,000 after acquiring an additional 194 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in shares of Atrion in the third quarter valued at approximately $333,000. Finally, WINTON GROUP Ltd purchased a new position in Atrion in the 3rd quarter valued at approximately $208,000. 66.19% of the stock is currently owned by hedge funds and other institutional investors.

Atrion Trading Up 6.3 %

Shares of ATRI stock opened at $420.00 on Tuesday. The company has a market cap of $739.20 million, a P/E ratio of 38.08 and a beta of 0.60. The firm has a fifty day moving average price of $406.12 and a 200 day moving average price of $364.66. Atrion Co. has a 12 month low of $274.98 and a 12 month high of $622.99.

Atrion (NASDAQ:ATRI) last released its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. The business had revenue of $43.58 million for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%.

Atrion Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were issued a $2.20 dividend. This represents a $8.80 annualized dividend and a dividend yield of 2.10%. The ex-dividend date was Thursday, March 14th. Atrion’s payout ratio is 79.78%.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Atrion from a “hold” rating to a “sell” rating in a report on Monday, April 22nd.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.